A practical reference on peptide mapping: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-07 and is reviewed periodically as new material appears.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
At the end of its ten-year license, BMS re-formulated Videx as Videx EC and patented that, which reformulation the FDA approved in 2000. The new formulation is a smaller capsule containing coated microspheres instead of using a buffering compound. It is approved by the FDA for once-a-day dosing. Also at the end of that ten-year period, the NIH licensed didanosine to Barr Laboratories under a non-exclusive license, and didanosine became the first generic anti-HIV drug marketed in the United States. One of the patents for ddI expired in the United States on 29 August 2006, but other patents extend beyond that time.
A few incidents have occurred when radioactive material was disposed of improperly, shielding during transport was defective, or when it was simply abandoned or even stolen from a waste store. In the Soviet Union, waste stored in Lake Karachay was blown over the area during a dust storm after the lake had partly dried out. In Italy, several radioactive waste deposits let material flow into river water, thus contaminating water for domestic use. In France in the summer of 2008, numerous incidents happened: in one, at the Areva plant in Tricastin, it was reported that, during a draining operation, liquid containing untreated uranium overflowed out of a faulty tank and about 75 kg of the radioactive material seeped into the ground and, from there, into two rivers nearby; in another case, over 100 staff were contaminated with low doses of radiation. There are ongoing concerns around the deterioration of the nuclear waste site on the Enewetak Atoll of the Marshall Islands and a potential radioactive spill. Scavenging of abandoned radioactive material has been the cause of several other cases of radiation exposure, mostly in developing nations, which may have less regulation of dangerous substances (and sometimes less general education about radioactivity and its hazards) and a market for scavenged goods and scrap metal. The scavengers and those who buy the material are almost always unaware that the material is radioactive and it is selected for its aesthetics or scrap value.
Urocortin III, a 38–41 amino acid peptide, is a member of the CRF (corticotropin-releasing factor), also known as CRH (corticotropin-releasing hormone) family of peptides, with a long evolutionary lineage. Separate chromosomes harbouring two exons each are home to the genes encoding UCN, UCN2, and UCN3. A gene on human chromosome 10p15 at location 5.40 Mb encodes the urocortin, UCN III, which has been discovered more recently. A 161 amino acid precursor is produced when the UCN III gene is translated. Mature UCN III with 38 or 41 amino acids would be produced by proteolytic cleavage between arginine- or threonine-lysine residues. Human plasma contains both the 38 and 41 amino acid forms of UCN III, although the 38 amino acid form is more prevalent, according to findings from high-performance liquid chromatography. Each urocortin peptide has a distinct expression location and function, yet they all share conserved structural similarity. Urocortins' structures, as determined by nuclear magnetic resonance, exhibit alpha-helical secondary structures, which support biological activity and binding selectivity.
Sources: en.wikipedia.org
Christine Coates, Director, Coates Engineering (International Ltd). For services to Economic Development in North West England. Paulene Mary Collins. For services to Legal Education. Charles John Cooper, Principal Professional and Technology Officer, Ministry of Defence. Derek MacDonald Cooper. For services to Radio Broadcasting. Commodore George Richard Cooper, , Chief of Operations, Royal National Lifeboat Institution. For services to the RNLI. David Leonard Court. For services to Tourism in East Anglia. The Honourable Jurat John Alexander Gore Coutanche, lately Jurat, Royal Court of Jersey. For services to the community. Squadron Leader Robert Frederick Craig, Royal Air Force (Retd.), lately Grade 7, Ministry of Defence. Adrian Robert Currie, , Chief Fire Officer, Devon Fire and Rescue Service. For services to the Fire Service. Professor John Darby. For services to Community Relations. William Roch Davies, lately Director, Welsh Centre for International Affairs. For humanitarian services. Sally Dawn Ridley-Day. For political and public service. Peter Denley. For services to the Rehabilitation of Offenders. Brian Charles Dice. For services to British Waterways. James Dick, Director of Social Work Services, The Highland Council. For services to Social Work. Elizabeth Ann Dodsworth. For political service. Margaret Duddy. For political and public service. Andrew Nicholas Duff. For political service. Sister Mary Vincent Duggan. For services to Education. Helen Simpson Dunsmore. For services to Higher Education. Albert John Edwards, .
Santosh Shivaji Lad (born 27 February 1975) is an Indian politician from Karnataka and a member of the Indian National Congress. He has been elected to the Karnataka Legislative Assembly four times, first from Sandur in 2004 and subsequently from Kalaghatgi in 2008, 2013 and 2023. He currently serves as the Cabinet Minister for Labour and Employment in Government of Karnataka, and is a member of Karnataka Legislative Assembly representing Kalaghatgi-Alnavar constituency in the Dharwad district of Karnataka state. Lad has served as a minister in successive Karnataka governments. He served as Minister of State for Information and Infrastructure Development in the Siddaramaiah ministry from 2013, resigned from the ministry in November 2013 following allegations concerning illegal mining involving his company, and returned to the state cabinet in 2016 as Labour Minister, later also holding the Skill Development portfolio.
Stark attributes the rise of the movement in the late-19th and early-20th centuries to several factors, chiefly that medical practice was in its infancy. Because patients often fared better without medical treatment, Christian Science prayer was favorable in comparison. Other factors included that the church retained cultural continuity with Christianity by stressing that it was Christian and adopting its terms, despite the new content Eddy introduced. It was not puritanical. Members were expected not to drink or smoke, but could otherwise do as they pleased, and several exceptions to the avoidance of medicine were permitted. In 1906, 72 percent of Christian Scientists in the United States were female, against 49 percent of the population. The church was attractive to women because it offered professional opportunities when it was difficult for women to find work outside the home. As Christian Scientists they could become practitioners after just 12 lessons. Of the 14 practitioners listed in the first edition of the Christian Science Journal, 12 were women. The increased efficacy of medicine around World War II heralded the religion's decline. Stark charts the use of sulfonamide to kill bacteria, the availability of penicillin in the 1940s and breakthroughs in immunology. Other factors were increased career opportunities for women, and that much of the membership was elderly. In 1998 30 percent of Christian Scientists were over 65. Eddy was in her sixties by the time the movement began to spread.
Breast augmentation (also breast enlargement) is a plastic surgery procedure by which either a breast implant or a fat-graft implant is emplaced to the thorax to increase the size of the breasts in order to correct congenital defects of the breast and of the chest wall. Consequently, after the breast-enlargement surgery, the symmetrical breast hemisphere is of proportionate size, has a smooth contour, and is anatomically consistent with the woman's body. Three therapeutic purposes require the emplacement of a prosthetic breast: (i) primary reconstruction surgery of the chest and breast tissues damaged by breast cancer, blunt trauma, penetrating trauma, and blast injury; and of developmental defects of the thoracic anatomy, e.g. the tuberous breast deformity; (ii) the surgical revision and reconstruction of chest-and-breast-tissue complications arisen from a previous mammoplasty; and (iii) primary augmentation to surgically enhance the aesthetics of the bust and the breasts. To augment the volume of the breast hemisphere, a prosthetic breast (saline or silicone) establishes the initial spherical augmentation of the breast for contouring by the plastic surgeon. To augment the volume of the breast hemisphere with autologous adipocyte tissue, the surgeon injects the woman's refined body-fat into the skin envelope to correct contour defects of the breast hemisphere. A fat-graft breast augmentation yields a breast-size increase is of modest volume, usually one brassière cup-size, consequent to the body's usual resorbtion of most of the autologous fat-graft.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.